Comparison of the safety and efficacy of remimazolam for sedation during bronchoscopy: a meta-analysis of randomized controlled trials
PeerJ · 2026
DOI: 10.7717/peerj.20552 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PeerJ, 2026. Verfasst von Yupei Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Hypnotics and Sedatives, Bronchoscopy, Benzodiazepines, Procedural Sedation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Distinguished Young Scholars-Natural Science Foundation of Xinjiang Uygur Autonomous Region.
Abstract (Originalsprache)
Objective
To evaluate the comparative efficacy and safety of remimazolam vs . established sedatives (dexmedetomidine, propofol, midazolam) for sedation during bronchoscopy.
Methods
A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA guidelines and Cochrane Handbook recommendations (PROSPERO CRD420251071986). Databases (EMBASE, PubMed, Scopus, Cochrane Central, Web of Science) were searched from inception to May 14, 2025. Included studies were RCTs comparing intravenous remimazolam to comparator sedatives in adults (≥18 years) undergoing bronchoscopy. Primary outcome was procedural success rate (completion without rescue sedation). Secondary outcomes included onset time, wake-up time, procedure duration, patient satisfaction, and adverse events (hypotension, hypoxemia, tachycardia, bradycardia, hypertension). Risk of bias was assessed using RoB 2. Data were pooled using random-effects models, reporting mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI).
Results
13 RCTs ( n = 2,002 patients) were included. Remimazolam demonstrated: Procedural success: Significantly higher success rates vs . dexmedetomidine (OR 2.87, 95% CI [1.13–7.29], P = 0.03; I 2 = 62%) and vs . midazolam (OR 3.65, 95% CI [1.40–9.49], P = 0.008; absolute rates 77.1% vs . 3.6%). Comparable success rates to propofol (OR 0.55, 95% CI [0.11–2.61], P = 0.45; rates ~98% each). Onset/Recovery: Faster onset vs . dexmedetomidine (MD −2.01 min, 95% CI [−2.08 to −1.93], P < 0.001; I 2 = 0%). Shorter wake-up time vs . dexmedetomidine (MD −1.84 min, 95% CI [−3.31 to −0.37], P = 0.01) and vs . midazolam (MD −4.72 min, 95% CI [−8.05 to −1.39], P = 0.005). Comparisons with propofol were inconclusive due to heterogeneity. Safety: Significantly lower risk of hypotension vs . propofol (OR 0.35, 95% CI [0.23–0.55], P < 0.00001) and hypoxemia vs . dexmedetomidine (OR 0.41, 95% CI [0.18–0.96], P = 0.04). Significantly higher risk of tachycardia vs . dexmedetomidine (OR 3.01, 95% CI [1.37–6.60], P = 0.006). No significant safety differences vs . midazolam. Patient satisfaction was equivalent to propofol.
Conclusion
Remimazolam is a highly effective and safe sedative for bronchoscopy. It offers superior procedural success and faster recovery compared to dexmedetomidine and midazolam, while matching the high success rate of propofol. Its key safety advantage is significantly reduced hypotension risk compared to propofol, making it particularly suitable for vulnerable patients. Remimazolam represents a valuable addition to sedation options for this procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
- The Fourth Clinical Medical College of Xinjiang Medical University, Urumqi, China.
- Department of Psychology, The Fourth Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Urumqi, China.
Förderung
- Distinguished Young Scholars-Natural Science Foundation of Xinjiang Uygur Autonomous Region
Zitieren
APA
Yuan, Y., Chang, C., Zhang, J., & Liang, L. (2026). Comparison of the safety and efficacy of remimazolam for sedation during bronchoscopy: a meta-analysis of randomized controlled trials. PeerJ. https://doi.org/10.7717/peerj.20552
Vancouver
Yuan Y, Chang C, Zhang J, Liang L. Comparison of the safety and efficacy of remimazolam for sedation during bronchoscopy: a meta-analysis of randomized controlled trials. PeerJ. 2026. doi:10.7717/peerj.20552
BibTeX
@article{Yuan2026,
author = {Yuan, Yupei and Chang, Chunlei and Zhang, Jing and Liang, Liang},
title = {Comparison of the safety and efficacy of remimazolam for sedation during bronchoscopy: a meta-analysis of randomized controlled trials},
journal = {PeerJ},
year = {2026},
doi = {10.7717/peerj.20552}
}
EUVIMED